Hepatic arterial chemotherapy in metastatic colorectal patients.

摘要: Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale hepatic arterial chemotherapy has both an anatomical pharmacological basis. Several randomized clinical studies fluoropyrimidine showed higher response rates in all trials when the drug was given as infusion (HAI) versus systemic administration. However, did not accurately define survival following reasons: (1) some allowed crossover; (2) were too small; (3) used inadequate chemotherapy. Patients who have failed to respond previous approximately 50% rate HAI treatment. toxicity, especially biliary sclerosis, is dose-limiting occurring 6% 25% patients. Adding dexamethasone decreases hepatobiliary toxicity. therapeutic benefit one study also demonstrated by increased time normal quality life. To truly role regional therapy CRC confined liver, current Cancer Leukemia Group B (CALGB) randomizing without crossover demonstrate if improves and/or life addition rates.